Cargando…

Rescue combination treatment of anti-MDA5-associated ARDS with daratumumab

Detalles Bibliográficos
Autores principales:	Ostendorf, Lennard, Muench, Frédéric, Thormählen, Lena, Galbavý, Zaza, Körner, Roland, Nee, Jens, Schneider, Udo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Myositis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364176/ https://www.ncbi.nlm.nih.gov/pubmed/37479497 http://dx.doi.org/10.1136/rmdopen-2023-003238

Ejemplares similares

Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease
por: Chen, Xixia, et al.
Publicado: (2023)

Intramuscular lesions in musculoskeletal MRI as a favourable prognostic sign in patients with anti-MDA5 antibody-positive dermatomyositis
por: Oto, Yohsuke, et al.
Publicado: (2023)

Aberrant Muscle Antigen Exposure in Mice Is Sufficient to Cause Myositis in a Treg Cell–Deficient Milieu
por: Young, Nicholas A, et al.
Publicado: (2013)

Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups
por: Rothwell, Simon, et al.
Publicado: (2019)

[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis
por: Lilleker, James B, et al.
Publicado: (2019)

Immune‐Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA–DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum
por: Rothwell, Simon, et al.
Publicado: (2017)

Muscle Weakness in Myositis: MicroRNA‐Mediated Dystrophin Reduction in a Myositis Mouse Model and Human Muscle Biopsies
por: Kinder, Travis B., et al.
Publicado: (2020)

Familial aggregation and heritability: a nationwide family-based study of idiopathic inflammatory myopathies
por: Che, Weng Ian, et al.
Publicado: (2021)

Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies
por: Zhou, Danlei, et al.
Publicado: (2023)

Immunoproteasome subunit β5i promotes perifascicular muscle atrophy in dermatomyositis by upregulating RIG-I
por: Zhang, Lu, et al.
Publicado: (2023)

Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis
por: Wilkinson, Meredyth G Ll, et al.
Publicado: (2023)

Severe case of rhabdomyolysis following jellyfish envenomation in the Mediterranean Sea
por: Buscetta, Giorgio, et al.
Publicado: (2023)

Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments
por: Kawahata, Kimito, et al.
Publicado: (2023)

In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case–control study
por: Pijnenburg, Luc, et al.
Publicado: (2023)

Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort
por: Zanatta, Elisabetta, et al.
Publicado: (2023)

Daratumumab for the treatment of refractory ANCA-associated vasculitis
por: Ostendorf, Lennard, et al.
Publicado: (2023)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
por: Plesner, Torben
Publicado: (2021)

Increased levels of immature and activated low density granulocytes and altered degradation of neutrophil extracellular traps in granulomatosis with polyangiitis
por: Lipka, Spyridon, et al.
Publicado: (2023)

Effective and Safe Use of Glucocorticosteroids for Rescue of Late ARDS
por: Diana, Paolo, et al.
Publicado: (2017)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Steroids are part of rescue therapy in ARDS patients with refractory hypoxemia: no
por: Thompson, B. Taylor, et al.
Publicado: (2016)

Successful use of inhaled epoprostenol as rescue therapy for pediatric ARDS
por: Urich, Alissa, et al.
Publicado: (2020)

Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis
por: Ratuszny, Dominica, et al.
Publicado: (2020)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Infection Risk Associated with Daratumumab
por: Johnsrud, Joyce J, et al.
Publicado: (2017)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

The standard of care of patients with ARDS: ventilatory settings and rescue therapies for refractory hypoxemia
por: Bein, Thomas, et al.
Publicado: (2016)

Case Report: Eculizumab and ECMO Rescue Therapy of Severe ARDS in Goodpasture Syndrome
por: Sobotta, Michael, et al.
Publicado: (2021)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

New dawn of cellular therapies in autoimmune diseases
por: Wagner, Dimitrios Laurin, et al.
Publicado: (2023)

Daratumumab-induced transient myopic shift
por: Mavrommatis, Maria A., et al.
Publicado: (2018)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Daratumumab for immune thrombotic thrombocytopenic purpura
por: van den Berg, Jana, et al.
Publicado: (2022)

Role of Daratumumab in Cardiac AL Amyloidosis
por: Gertz, Morie A.
Publicado: (2022)

Daratumumab monotherapy for refractory lupus nephritis
por: Roccatello, Dario, et al.
Publicado: (2023)

Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies
por: Oldroyd, Alexander, et al.
Publicado: (2018)

Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies
por: Nombel, Anaïs, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g5go2qpgflga9slmc2t3qme5pn